Sefik Hosal A. Unusual tumours of the oral cavity and oropharynx. In: Belkacémi Y, Mirimanoff R-O, Ozsahin M, editors. Administration of uncommon grownup tumours. Paris: Springer Paris; 2010. p. 97–104.
Kaneko T, Suefuji H, Koto M, Demizu Y, Saitoh J-I, Tsuji H, et al. Multicenter research of carbon-ion radiotherapy for oropharyngeal non-squamous cell carcinoma. In Vivo. 2021;35:2239.
Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal most cancers incidence in the US. J Clin Oncol. 2011;29:4294–301.
Jemal A, Simard EP, Dorell C, Noone A-M, Markowitz LE, Kohler B, et al. Annual report back to the nation on the standing of most cancers, 1975–2009, that includes the burden and traits in human papillomavirus (HPV)–related cancers and HPV vaccination protection ranges. J Natl Most cancers Inst. 2013;105:175–201.
Faraji F, Rettig EM, Tsai H-L, El Asmar M, Fung N, Eisele DW, et al. The prevalence of human papillomavirus in oropharyngeal most cancers is growing no matter intercourse or race, and the affect of intercourse and race on survival is modified by human papillomavirus tumor standing. Most cancers. 2019;125:761–9.
Haeggblom L, Attoff T, Yu J, Holzhauser S, Vlastos A, Mirzae L, et al. Modifications in incidence and prevalence of human papillomavirus in tonsillar and base of tongue most cancers throughout 2000-2016 within the Stockholm area and Sweden. Head Neck. 2019;41:1583–90.
Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Proof for a causal affiliation between human papillomavirus and a subset of head and neck cancers. J Natl Most cancers Inst. 2000;92:709–20.
Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide traits in incidence charges for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31:4550–9.
Lechner M, Jones OS, Breeze CE, Gilson R. Gender-neutral HPV vaccination within the UK, rising male oropharyngeal most cancers charges, and lack of HPV consciousness. Lancet Infect Dis. 2019;19:131–2.
Wittekindt C, Wagner S, Bushnak A, Prigge E-S, von Knebel Doeberitz M, Würdemann N, et al. Growing incidence charges of oropharyngeal squamous cell carcinoma in Germany and significance of illness burden attributed to human papillomavirus. Most cancers Prev Res. 2019;12:375–82.
Zamani M, Grønhøj C, Jensen DH, Carlander AF, Agander T, Kiss Ok, et al. The present epidemic of HPV-associated oropharyngeal most cancers: an 18-year Danish population-based research with 2,169 sufferers. Eur J Most cancers. 2020;134:52–9.
Combes J-D, Franceschi S. Position of human papillomavirus in non-oropharyngeal head and neck cancers. Oral Oncol. 2014;50:370–9.
Castellsagué X, Alemany L, Quer M, Halec G, Quirós B, Tous S, et al. HPV involvement in head and neck cancers: complete evaluation of biomarkers in 3680 sufferers. J Natl Most cancers Inst. 2016;108:407–20.
Mahal BA, Catalano PJ, Haddad RI, Hanna GJ, Kass JI, Schoenfeld JD, et al. Incidence and demographic burden of HPV-associated oropharyngeal head and neck cancers in the US. Most cancers Epidemiol Biomark Prev.2019;28:1660–7.
D’Souza G, Westra WH, Wang SJ, van Zante A, Wentz A, Kluz N, et al. Variations within the prevalence of human papillomavirus (HPV) in head and neck squamous cell cancers by intercourse, race, anatomic tumor web site, and HPV detection methodology. JAMA Oncol. 2017;3:169–77.
Damgacioglu H, Sonawane Ok, Zhu Y, Li R, Balasubramanian BA, Lairson DR, et al. Oropharyngeal most cancers incidence and mortality traits in all 50 states within the US, 2001-2017. JAMA Otolaryngol–Head Neck Surg. 2022;148:155–65.
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of sufferers with oropharyngeal most cancers. N. Engl J Med. 2010;363:24–35.
Anantharaman D, Muller DC, Lagiou P, Ahrens W, Holcátová I, Merletti F, et al. Mixed results of smoking and HPV16 in oropharyngeal most cancers. Int J Epidemiol. 2016;45:752–61.
Zumsteg ZS, Cook dinner-Wiens G, Yoshida E, Shiao SL, Lee NY, Mita A, et al. Incidence of oropharyngeal most cancers amongst aged sufferers in the US. JAMA Oncol. 2016;2:1617–23.
Dickstein DR, Egerman MA, Bui AH, Doucette JT, Sharma S, Liu J, et al. A brand new face of the HPV epidemic: oropharyngeal most cancers within the aged. Oral Oncol. 2020;109:104687.
Rettig EM, Fakhry C, Khararjian A, Westra WH. Age profile of sufferers with oropharyngeal squamous cell carcinoma. JAMA Otolaryngol–Head Neck Surg. 2018;144:538–9.
Giuliano AR, Felsher M, Waterboer T, Mirghani H, Mehanna H, Roberts C, et al. Oral human papillomavirus prevalence and genotyping amongst a wholesome grownup inhabitants within the US. JAMA Otolaryngol–Head Neck Surg. 2023;149:783–95.
Gillison ML, Broutian T, Pickard RKL, Tong Z-y, Xiao W, Kahle L, et al. Prevalence of oral HPV an infection in the US, 2009-2010. JAMA. 2012;307:693–703.
Windon MJ, D’Souza G, Rettig EM, Westra WH, van Zante A, Wang SJ, et al. Growing prevalence of human papillomavirus–constructive oropharyngeal cancers amongst older adults. Most cancers. 2018;124:2993–9.
Rettig EM, Zaidi M, Faraji F, Eisele DW, El Asmar M, Fung N, et al. Oropharyngeal most cancers is not a illness of youthful sufferers and the prognostic benefit of Human Papillomavirus is attenuated amongst older sufferers: evaluation of the Nationwide Most cancers Database. Oral Oncol. 2018;83:147–53.
Fakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal D, El-Naggar A, Backyard AS, et al. Human papillomavirus and total survival after development of oropharyngeal squamous cell carcinoma. J Clin Oncol. 2014;32:3365–73.
Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal most cancers (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393:40–50.
Yom SS, Torres-Saavedra P, Caudell JJ, Waldron JN, Gillison ML, Xia P, et al. Decreased-dose radiation remedy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002). J Clin Oncol. 2021;39:956–65.
Jellema AP, Slotman BJ, Doornaert P, Leemans CR, Langendijk JA. Affect of radiation-induced xerostomia on high quality of life after main radiotherapy amongst sufferers with head and neck most cancers. Int J Radiat Oncol, Biol, Phys. 2007;69:751–60.
Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Affect of late treatment-related toxicity on high quality of life amongst sufferers with head and neck most cancers handled with radiotherapy. J Clin Oncol. 2008;26:3770–6.
Youssef I, Yoon J, Mohamed N, Zakeri Ok, Press RH, Chen L, et al. Toxicity profiles and survival outcomes amongst sufferers with nonmetastatic oropharyngeal carcinoma handled with intensity-modulated proton remedy vs intensity-modulated radiation remedy. JAMA Netw Open. 2022;5:e2241538–e.
Lim YX, Mierzwa ML, Sartor MA, D’Silva NJ. Scientific, morphologic and molecular heterogeneity of HPV-associated oropharyngeal most cancers. Oncogene 2023; 42, 2939–55.
Kreimer AR, Chaturvedi AK. HPV-associated oropharyngeal cancers—are they preventable? Most cancers Prev Res. 2011;4:1346–9.
Gillison ML, Akagi Ok, Xiao W, Jiang B, Pickard RKL, Li J, et al. Human papillomavirus and the panorama of secondary genetic alterations in oral cancers. Genome Res. 2019;29:1–17.
Chae J, Park WS, Kim MJ, Jang SS, Hong D, Ryu J, et al. Genomic characterization of clonal evolution throughout oropharyngeal carcinogenesis pushed by human papillomavirus 16. BMB Rep. 2018;51:584–9.
McIlwain WR, Sood AJ, Nguyen SA, Day TA. Preliminary signs in sufferers With HPV-positive and HPV-negative oropharyngeal most cancers. JAMA Otolaryngol–Head Neck Surg. 2014;140:441–7.
Guggenheimer J, Verbin RS, Johnson JT, Horkowitz CA, Myers EN. Components delaying the analysis of oral and oropharyngeal carcinomas. Most cancers. 1989;64:932–5.
Kero Ok, Rautava J, Syrjänen Ok, Grenman S, Syrjänen S. Oral mucosa as a reservoir of human papillomavirus: level prevalence, genotype distribution, and incident infections amongst males in a 7-year potential research. Eur Urol. 2012;62:1063–70.
Agalliu I, Gapstur S, Chen Z, Wang T, Anderson RL, Teras L, et al. Associations of oral α-, β-, and γ-human papillomavirus varieties with danger of incident head and neck most cancers. JAMA Oncol. 2016;2:599–606.
Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagué X, Laporte L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a scientific assessment and meta-analysis. Lancet Oncol. 2014;15:1319–31.
Mehanna H, Taberna M, von Buchwald C, Tous S, Brooks J, Mena M, et al. Prognostic implications of p16 and HPV discordance in oropharyngeal most cancers (HNCIG-EPIC-OPC): a multicentre, multinational, particular person affected person information evaluation. Lancet Oncol. 2023;24:239–51.
D’Souza G, Fakhry C, Sugar EA, Seaberg EC, Weber Ok, Minkoff HL, et al. Six-month pure historical past of oral versus cervical human papillomavirus an infection. Int J Most cancers. 2007;121:143–50.
Cañadas MP, Bosch FX, Junquera ML, Ejarque M, Font R, Ordoñez E, et al. Concordance of prevalence of human papillomavirus DNA in anogenital and oral infections in a high-risk inhabitants. J Clin Microbiol. 2004;42:1330–2.
Andrew FB, Lora PC, Heather MW, Brittany MM, Christine MG, Trey BT, et al. Incidence and clearance of oral and cervicogenital HPV an infection: longitudinal evaluation of the MHOC cohort research. BMJ Open. 2022;12:e056502.
Steinau M, Hariri S, Gillison ML, Broutian TR, Dunne EF, Tong Z-y, et al. Prevalence of cervical and oral human papillomavirus infections amongst US ladies. J Infect Dis. 2013;209:1739–43.
Dahlstrom KR, Burchell AN, Ramanakumar AV, Rodrigues A, Tellier P-P, Hanley J, et al. Sexual transmission of oral human papillomavirus an infection amongst males. Most cancers Epidemiol Biomark Prev. 2014;23:2959–64.
D’Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oral sexual behaviors related to prevalent oral human papillomavirus an infection. J Infect Dis. 2009;199:1263–9.
D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case–management research of human papillomavirus and oropharyngeal most cancers. N Engl J Med. 2007;356:1944–56.
Beachler DC, Weber KM, Margolick JB, Strickler HD, Cranston RD, Burk RD, et al. Threat elements for oral HPV an infection amongst a excessive prevalence inhabitants of HIV-positive and at-risk HIV-negative adults. Most cancers Epidemiol Biomark Prev. 2012;21:122–33.
Edelstein ZR, Schwartz SM, Hawes S, Hughes JP, Feng Q, Stern ME, et al. Charges and determinants of oral human papillomavirus an infection in younger males. Intercourse Transm Dis. 2012;39(11): 860–67.
Drake VE, Fakhry C, Windon MJ, Stewart CM, Akst L, Hillel A, et al. Timing, quantity, and sort of sexual companions related to danger of oropharyngeal most cancers. Most cancers. 2021;127:1029–38.
Wierzbicka M, San Giorgi MRM, Dikkers FG. Transmission and clearance of human papillomavirus an infection within the oral cavity and its position in oropharyngeal carcinoma—a assessment. Rev Med Virol. 2023;33:e2337.
Rintala MAM, Grénman SE, Puranen MH, Isolauri E, Ekblad U, Kero PO, et al. Transmission of high-risk human papillomavirus (HPV) between dad and mom and toddler: a potential research of HPV in households in Finland. J Clin Microbiol. 2005;43:376–81.
Chen R, Sehr P, Waterboer T, Leivo I, Pawlita M, Vaheri A, et al. Presence of DNA of human papillomavirus 16 however no different varieties in tumor-free tonsillar tissue. J Clin Microbiol. 2005;43:1408–10.
Schelhaas M, Shah B, Holzer M, Blattmann P, Kühling L, Day PM, et al. Entry of human papillomavirus kind 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLOS Pathog. 2012;8:e1002657.
Spoden G, Kühling L, Cordes N, Frenzel B, Sapp M, Boller Ok, et al. Human papillomavirus varieties 16, 18, and 31 share comparable endocytic necessities for entry. J Virol. 2013;87:7765–73.
DiGiuseppe S, Bienkowska-Haba M, Hilbig L, Sapp M. The nuclear retention sign of HPV16 L2 protein is crucial for incoming viral genome to transverse the trans-Golgi community. Virology. 2014;458-459:93–105.
Lipovsky A, Popa A, Pimienta G, Wyler M, Bhan A, Kuruvilla L, et al. Genome-wide siRNA display identifies the retromer as a mobile entry issue for human papillomavirus. Proc Natl Acad Sci USA. 2013;110:7452–7.
Popa A, Zhang W, Harrison MS, Goodner Ok, Kazakov T, Goodwin EC, et al. Direct binding of retromer to human papillomavirus kind 16 minor capsid protein L2 mediates endosome exit throughout viral an infection. PLOS Pathog. 2015;11:e1004699.
Crite M, DiMaio D. Human papillomavirus L2 capsid protein stabilizes γ-secretase throughout viral an infection. Viruses. 2022;14:804.
Inoue T, Zhang P, Zhang W, Goodner-Bingham Ok, Dupzyk A, DiMaio D, et al. γ-Secretase promotes membrane insertion of the human papillomavirus L2 capsid protein throughout virus an infection. J Cell Biol. 2018;217:3545–59.
Zhang W, Kazakov T, Popa A, DiMaio D, Dermody TS. Vesicular trafficking of incoming human papillomavirus 16 to the Golgi equipment and endoplasmic reticulum requires γ-secretase exercise. mBio 2014;5:e01777–14.
Calton CM, Bronnimann MP, Manson AR, Li S, Chapman JA, Suarez-Berumen M, et al. Translocation of the papillomavirus L2/vDNA advanced throughout the limiting membrane requires the onset of mitosis. PLOS Pathog. 2017;13:e1006200.
Bienkowska-Haba M, Williams C, Kim SM, Garcea RL, Sapp M. Cyclophilins facilitate dissociation of the human papillomavirus kind 16 capsid protein l1 from the L2/DNA advanced following virus entry. J Virol. 2012;86:9875–87.
Aydin I, Weber S, Snijder B, Samperio Ventayol P, Kühbacher A, Becker M, et al. Massive scale RNAi reveals the requirement of nuclear envelope breakdown for nuclear import of human papillomaviruses. PLOS Pathog. 2014;10:e1004162.
Pyeon D, Pearce SM, Lank SM, Ahlquist P, Lambert PF. Institution of human papillomavirus an infection requires cell cycle development. PLOS Pathog. 2009;5:e1000318.
DiGiuseppe S, Luszczek W, Keiffer TR, Bienkowska-Haba M, Guion LG, Sapp MJ. Incoming human papillomavirus kind 16 genome resides in a vesicular compartment all through mitosis. Proc Natl Acad Sci. 2016;113:6289–94.
Rizzato M, Mao F, Chardon F, Lai Ok-Y, Villalonga-Planells R, Drexler HCA, et al. Grasp mitotic kinases regulate viral genome supply throughout papillomavirus cell entry. Nat Commun. 2023;14:355.
Egawa N, Nakahara T, Ohno S-i, Narisawa-Saito M, Yugawa T, Fujita M, et al. The E1 protein of human papillomavirus kind 16 is dispensable for upkeep replication of the viral genome. J Virol. 2012;86:3276–83.
Graham Sheila V, Sullivan CS. Human papillomavirus E2 protein: linking replication, transcription, and RNA processing. J Virol. 90:8384–8.
Tine BAV, Dao LD, Wu S-Y, Sonbuchner TM, Lin BY, Zou N, et al. Human papillomavirus (HPV) origin-binding protein associates with mitotic spindles to allow viral DNA partitioning. Proc Natl Acad Sci. 2004;101:4030–5.
Oliveira JG, Colf LA, McBride AA. Variations within the affiliation of papillomavirus E2 proteins with mitotic chromosomes. Proc Natl Acad Sci. 2006;103:1047–52.
Maglennon GA, McIntosh P, Doorbar J. Persistence of viral DNA within the epithelial basal layer suggests a mannequin for papillomavirus latency following immune regression. Virology. 2011;414:153–63.
White EA. Manipulation of epithelial differentiation by HPV oncoproteins. Viruses. 2019;11:369.
Cheng S, Schmidt-Grimminger DC, Murant T, Dealer TR, Chow LT. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates mobile DNA replication in suprabasal differentiated keratinocytes. Genes Dev 1995;9:2335–49.
Yukawa Ok, Butz Ok, Yasui T, Kikutani H, Hoppe-Seyler F. Regulation of human papillomavirus transcription by the differentiation-dependent epithelial issue Epoc-1/skn-1a. J Virol. 1996;70:10–6.
Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant development. Oncogene. 2001;20:7874–87.
Wallace NA, Galloway DA. Novel features of the human papillomavirus E6 oncoproteins. Annu Rev Virol. 2015;2:403–23.
Ganti Ok, Broniarczyk J, Manoubi W, Massimi P, Mittal S, Pim D, et al. The human papillomavirus E6 PDZ binding motif: from life cycle to malignancy. Viruses. 2015;7:3530–3551.
Giarrè M, Caldeira S, Malanchi I, Ciccolini F, Leão MJ, Tommasino M. Induction of pRb degradation by the human papillomavirus kind 16 E7 protein is crucial to effectively overcome p16INK4a-imposed G1 cell cycle arrest. J Virol. 2001;75:4705–12.
Khleif SN, DeGregori J, Yee CL, Otterson GA, Kaye FJ, Nevins JR, et al. Inhibition of cyclin D-CDK4/CDK6 exercise is related to an E2F-mediated induction of cyclin kinase inhibitor exercise. Proc Natl Acad Sci. 1996;93:4350–4.
McLaughlin-Drubin ME, Crum CP, Münger Ok. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci. 2011;108:2130–5.
Hatterschide J, Bohidar AE, Grace M, Nulton TJ, Kim HW, Windle B, et al. PTPN14 degradation by high-risk human papillomavirus E7 limits keratinocyte differentiation and contributes to HPV-mediated oncogenesis. Proc Natl Acad Sci. 2019;116:7033–42.
Hatterschide J, Brantly AC, Grace M, Munger Ok, White EA. A conserved amino acid within the C terminus of human papillomavirus E7 mediates binding to PTPN14 and repression of epithelial differentiation. J Virol. 2020;94. https://doi.org/10.1128/jvi.01024-20.
Hatterschide J, Castagnino P, Kim HW, Sperry SM, Montone KT, Basu D, et al. YAP1 activation by human papillomavirus E7 promotes basal cell identification in squamous epithelia. eLife. 2022;11:e75466.
Müller M, Prescott EL, Wasson CW, Macdonald A. Human papillomavirus E5 oncoprotein: operate and potential goal for antiviral therapeutics. Future Virol. 2015;10:27–39.
Doorbar J. The E4 protein; construction, operate and patterns of expression. Virology. 2013;445:80–98.
Wasson CW, Morgan EL, Müller M, Ross RL, Hartley M, Roberts S, et al. Human papillomavirus kind 18 E5 oncogene helps cell cycle development and impairs epithelial differentiation by modulating progress issue receptor signalling throughout the virus life cycle. Oncotarget. 2017;8:103581–600.
Davy CE, Jackson DJ, Raj Ok, Peh WL, Southern SA, Das P, et al. Human papillomavirus kind 16 E1^E4-induced G2 arrest is related to cytoplasmic retention of lively Cdk1/Cyclin B1 complexes. J Virol. 2005;79:3998–4011.
Davy C, McIntosh P, Jackson DJ, Sorathia R, Miell M, Wang Q, et al. A novel interplay between the human papillomavirus kind 16 E2 and E1^E4 proteins results in stabilization of E2. Virology. 2009;394:266–75.
Johansson C, Somberg M, Li X, Backström Winquist E, Fay J, Ryan F, et al. HPV-16 E2 contributes to induction of HPV-16 late gene expression by inhibiting early polyadenylation. EMBO J. 2012;31:3212–27.
Khan J, Davy CE, McIntosh PB, Jackson DJ, Hinz S, Wang Q, et al. Position of calpain within the formation of human papillomavirus kind 16 E1^E4 amyloid fibers and reorganization of the keratin community. J Virol. 2011;85:9984–97.
Kreimer AR, Pierce Campbell CM, Lin H-Y, Fulp W, Papenfuss MR, Abrahamsen M, et al. Incidence and clearance of oral human papillomavirus an infection in males: the HIM cohort research. Lancet. 2013;382:877–87.
D’Souza G, Clemens G, Strickler HD, Wiley DJ, Troy T, Struijk L, et al. Lengthy-term persistence of oral HPV over 7 years of follow-up. JNCI Most cancers Spectrum. 2020;4:pkaa047.
Bettampadi D, Sirak BA, Abrahamsen ME, Reich RR, Villa LL, Ponce EL, et al. Components related to persistence and clearance of high-risk oral human papillomavirus (HPV) amongst members within the HPV an infection in males (HIM) research. Clin Infect Dis. 2020;73:e3227–e34.
Kreimer AR, Ferreiro-Iglesias A, Nygard M, Bender N, Schroeder L, Hildesheim A, et al. Timing of HPV16-E6 antibody seroconversion earlier than OPSCC: findings from the HPVC3 consortium. Ann Oncol. 2019;30:1335–43.
Garset-Zamani M, Carlander AF, Jakobsen KK, Friborg J, Kiss Ok, Marvig RL, et al. Affect of particular high-risk human papillomavirus genotypes on survival in oropharyngeal most cancers. Int J Most cancers. 2022;150:1174–83.
Mashiana SS, Navale P, Khandakar B, Sobotka S, Posner MR, Miles BA, et al. Human papillomavirus genotype distribution in head and neck most cancers: Informing growing methods for most cancers prevention, analysis, remedy and surveillance. Oral Oncol. 2021;113:105109.
LeConte BA, Szaniszlo P, Fennewald SM, Lou DI, Qiu S, Chen N-W, et al. Variations within the viral genome between HPV-positive cervical and oropharyngeal most cancers. PLOS ONE. 2018;13:e0203403.
Lewis JS Jr, Beadle B, Bishop JA, Chernock RD, Colasacco C, Lacchetti C, et al. Human papillomavirus testing in head and neck carcinomas: guideline from the Faculty of American Pathologists. Arch Pathol Lab Med. 2017;142:559–97.
Sung, H. et al. World Most cancers Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Nations. CA: A Most cancers Journal for Clinicians 2021;71:209–49. https://doi.org/10.3322/caac.21660.
Ferlay, J. et al. Most cancers statistics for the 12 months 2020: An outline. Worldwide Journal of Most cancers 2021;149:778–89. https://doi.org/10.1002/ijc.33588.
Ferlay J, L. M., Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. World Most cancers Observatory: Most cancers Tomorrow 2020. https://gco.iarc.fr/tomorrow.
Ferlay J, E. M., Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F World Most cancers Observatory: Most cancers At this time 2020. https://gco.iarc.fr/at present
Knowledge, O. W. i. Human Improvement Index 2017, 2022.
